Boehringer Ingelheim Venture Fund

company

About

Boehringer Ingelheim Venture Fund intends to invest in groundbreaking therapeutic approaches and technologies.

  • 11 - 50

Details

Industries
Biotechnology,Finance,Venture Capital
Founded date
Jan 1, 2010
Number Of Employee
11 - 50
Operating Status
Active
Investor Type
CVC

Boehringer Ingelheim Venture Fund GmbH (BIVF) invests in groundbreaking therapeutics-focused biotechnology companies to drive innovation in biomedical research. BIVF is searching for significant enhancements in patient care through pioneering science and its clinical translation by building long-term relationships with scientists and entrepreneurs. BIVF’s focus is to target unprecedented therapeutic concepts addressing high medical needs in immuno-oncology, regenerative medicine, infectious diseases and digital health. These may include novel platform technologies to address so far undruggable targets, new generation vaccines and/or new biological entities, such as oncolytic virotherapy.

Investments

Number of Investments
Number of Lead Investments
7
2
Boehringer Ingelheim Venture Fund has made 7 investments. Their most recent investment was on Nov 29, 2022, when Rgenta Therapeutics raised $52M.
Date Company Name
Round Money Raised Industry Lead Investor
Series A $52M Biotechnology
Seed $20M Biotechnology Yes
Series B €10M Biotechnology
Series A €27M Biotechnology
Series A €2.50M Biotechnology Yes